 Connection
Brooke Fridley to Pancreatic Neoplasms
This is a "connection" page, showing publications Brooke Fridley has written about Pancreatic Neoplasms.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.491 |
|
|
|
-
Li L, Zhang JW, Jenkins G, Xie F, Carlson EE, Fridley BL, Bamlet WR, Petersen GM, McWilliams RR, Wang L. Genetic variations associated with gemcitabine treatment outcome in pancreatic cancer. Pharmacogenet Genomics. 2016 Dec; 26(12):527-537.
Score: 0.144
-
Ellsworth KA, Eckloff BW, Li L, Moon I, Fridley BL, Jenkins GD, Carlson E, Brisbin A, Abo R, Bamlet W, Petersen G, Wieben ED, Wang L. Contribution of FKBP5 genetic variation to gemcitabine treatment and survival in pancreatic adenocarcinoma. PLoS One. 2013; 8(8):e70216.
Score: 0.114
-
Reid-Lombardo KM, Fridley BL, Bamlet WR, Cunningham JM, Sarr MG, Petersen GM. Survival is associated with genetic variation in inflammatory pathway genes among patients with resected and unresected pancreatic cancer. Ann Surg. 2013 Jun; 257(6):1096-102.
Score: 0.113
-
Reid-Lombardo KM, Fridley BL, Bamlet WR, Cunningham JM, Sarr MG, Petersen GM. Inflammation-related gene variants as risk factors for pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2011 Jun; 20(6):1251-4.
Score: 0.097
-
Pei H, Li L, Fridley BL, Jenkins GD, Kalari KR, Lingle W, Petersen G, Lou Z, Wang L. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell. 2009 Sep 08; 16(3):259-66.
Score: 0.022
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|